Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma

Hyery Kim; Hee Mang Yoon; Eun Key Kim; Young Cheol Shin; Hyo‐Won Kim; Mi‐Sun Yum; Min‐Jee Kim; Jae Suk Baek; Yu Sub Sung; Sang Min Lee; Hyeong-Seok Lim; Byung Joo Lee; Hyun Taek Lim; Dohyung Kim; Ji‐Hee Yoon; Hyunwoo Bae; Soojin Hwang; Yunha Choi; Kyung‐Ah Kim; In Hee Choi; Seungwon Lee; SuJung Park; Beom Hee Lee

doi:10.1093/neuonc/noae121

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The MEK inhibitor, selumetinib, reduces plexiform neurofibroma (PN) in pediatric patients with neurofibromatosis type 1 (NF1). Its safety and efficacy in adults with PN and effectiveness in other NF1 manifestations (eg, neurocognitive function, growth reduction, and café-au-lait spots) are unknown.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2024) studied this question.

synapsesocial.com/papers/68e60f70b6db6435875a2b88 https://doi.org/10.1093/neuonc/noae121

View Full Paper

Ask AI

Bookmark

Share

Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma

Ask about this paper

Abstract

Discussion

Cite This Study

Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading